Literature DB >> 31712879

Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.

Sung Kyun Yim1, Ho-Young Yhim1,2, Yeon-Hee Han3, So-Yeon Jeon1,2, Na-Ri Lee1,2, Eun-Kee Song1,2, Hwan-Jeong Jeong2,3, Hee Sun Kim4, Jae-Yong Kwak5,6.   

Abstract

The aim of this study was to evaluate the prognostic relevance of early risk stratification in diffuse large B-cell lymphoma (DLBCL) using interim Deauville score on positron emission tomography-computed tomography (PET-CT) scan and baseline International Prognostic Index (IPI). This retrospective study included 220 patients (median age, 64 years; men, 60%) diagnosed with DLBCL between 2007 and 2016 at our institution, treated with rituximab-based chemotherapy. Interim PET-CT was performed after three cycles of immuno-chemotherapy. Interim Deauville score was assessed as 4 or 5 in 49 patients (22.3%), and 94 patients (42.7%) had high-intermediate or high-risk IPI scores. In multivariate analysis, interim Deauville score (1-3 and 4-5) and baseline IPI (low/low-intermediate and high-intermediate/high) were independently associated with progression-free survival (for Deauville score, hazard ratio [HR], 1.00 vs. 2.96 [95% confidence interval (CI), 1.83-4.78], P < 0.001; for IPI, HR, 1.00 vs. 4.84 [95% CI, 2.84-8.24], P < 0.001). We stratified patients into three groups: low-risk (interim Deauville scores 1-3 and low/low-intermediate IPI), intermediate-risk (Deauville scores 1-3 with high-intermediate/high IPI or Deauville scores 4-5 with low/low-intermediate IPI), and high-risk (Deauville scores 4-5 and high-intermediate/high IPI). This early risk stratification showed a strong association with progression-free survival (HR, 1.00 vs. 3.98 [95% CI 2.10-7.54] vs. 13.97 [95% CI 7.02-27.83], P < 0.001). Early risk stratification using interim Deauville score and baseline IPI predicts the risk of disease progression or death in patients with DLBCL. Our results provide guidance with interim PET-driven treatment intensification strategies.

Entities:  

Keywords:  Deauville score; Diffuse large B-cell lymphoma; International Prognostic Index; Positron emission tomography-computed tomography; Risk stratification

Mesh:

Substances:

Year:  2019        PMID: 31712879     DOI: 10.1007/s00277-019-03834-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  Prognostic Role of Interim 18-Fluorodeoxyglucose-PET in Diffuse Large B Cell Lymphoma: Experience from a Tertiary Care Centre in North India.

Authors:  Sujeet Kumar; Anshul Gupta; Manish Ora; Khaliqur Rahman; Reena Choudhary; Soniya Nityanand
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-04       Impact factor: 0.900

2.  The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.

Authors:  Zahra Kiamanesh; Narjess Ayati; Ramin Sadeghi; Eliza Hawkes; Sze Ting Lee; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-06       Impact factor: 10.057

3.  A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT.

Authors:  Xiaohui Zhang; Lin Chen; Han Jiang; Xuexin He; Liu Feng; Miaoqi Ni; Mindi Ma; Jing Wang; Teng Zhang; Shuang Wu; Rui Zhou; Chentao Jin; Kai Zhang; Wenbin Qian; Zexin Chen; Cheng Zhuo; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

4.  Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.

Authors:  Jie Zhu; Yong Yang; Jin Tao; Shu-Lian Wang; Bo Chen; Jian-Rong Dai; Chen Hu; Shu-Nan Qi; Ye-Xiong Li
Journal:  Leukemia       Date:  2020-07-10       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.